Materialise (MTLS) Q3 2026 earnings summary

Executive summary

• Q3 revenue rose 2.1% YoY to €67.670M; growth was 4.9% excluding recent divestitures.

• Medical revenue grew 9.7%; Manufacturing grew 1.5% excluding divestitures. Net profit was €1.383M.

• Net cash reached €82.473M, up €11.668M from year-end 2025.

Financial highlights

• Gross profit rose 3.7% to €39.035M; gross margin was 57.7%, up 90 bps YoY.

• Adjusted EBIT was €2.485M vs. €2.918M; Adjusted EBITDA was €8.046M vs. €8.428M.

• Operating profit was €1.343M vs. €2.522M; net profit was €1.383M vs. €1.848M, with diluted EPS of €0.02 vs. €0.03.

• R&D, sales and marketing, and G&A expenses rose 7.8% to €38.830M, driven mainly by 11.9% higher R&D spending.

Outlook and guidance

• FY26 revenue guidance of €273M–€283M and Adjusted EBIT guidance of €12M–€14M were reaffirmed, absorbing the impact of RapidFit and Eyewear divestitures.

• Priorities include strategy execution, targeted investment, cost control and cash generation.